Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues
journal contributionposted on 18.11.2015, 00:00 by Xiuling Li, James T. Patterson, Mohosin Sarkar, Lee Pedzisa, Thomas Kodadek, William R. Roush, Christoph Rader
Site-specific conjugation technologies enable the production of homogeneous antibody–drug conjugates (ADCs) with improved therapeutic indices compared to conventional ADCs. However, current site-specific conjugation methods can only attach one type of drug to a single antibody. Given the emergence of acquired resistance to current ADCs, arming single antibodies with different drugs may provide an attractive option in the development of next-generation ADCs. Here, we describe a site-specific dual conjugation strategy as a platform for dual warhead ADCs.